Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7656594 in Advanced or Metastatic Prostate Cancer
NCT05800665Phase 1Recruiting
- Sponsor
- Genentech
- Start
- May 2023
- Primary completion
- Jun 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 7
01
Overview
Phase 1, open-label trial of JMKX002992 in prostate cancer (PCa) (2 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants with Adverse Events at 24 months and Percentage of Participants Who Experience Dose-limiting Toxicities at 28 days. Started May 2023; status: recruiting.
02
Drugs
JMKX002992
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05800665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800665.